• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 4 filed by President and CEO Romness Paul A.

    2/13/26 4:20:06 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OSTX alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Romness Paul A.

    (Last) (First) (Middle)
    C/O OS THERAPIES INCORPORATED
    115 PULLMAN CROSSING ROAD, SUITE 103

    (Street)
    GRASONVILLE MD 21638

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    OS Therapies Inc [ OSTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    10/21/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    12/19/2025
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 2,473,000 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock options (right to buy) $1.8 10/21/2025 A 1,000,000 (1) 10/21/2035 Common Stock 1,000,000 $0 1,000,000 D
    Explanation of Responses:
    1. On October 21, 2025, the reporting person was granted options to purchase 1,000,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date.
    Remarks:
    On December 19, 2025, the reporting person filed a Form 4 that incorrectly reported the number of shares of common stock underlying the stock option award grant in Table II. This amended Form 4 is being filed to correctly report in Table II the number of shares of common stock underlying the stock option award grant that occurred on October 21, 2025.
    /s/ Paul A. Romness 02/13/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OSTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSTX

    DatePrice TargetRatingAnalyst
    4/2/2025$19.00Buy
    Lake Street
    More analyst ratings

    $OSTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

    Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma regulatory advice and oncology pipeline prioritizationNew York, New York--(Newsfile Corp. - April 8, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced that Craig Eagle, MD, was appointed to the Company's newly-formed strategic advisory board. The Company's strategic advisory board is being formed to assist the Company in fine-tuning its osteosarcoma regulatory execution plan and to help develop a detailed pipeline

    4/8/26 11:38:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors

    Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26Company expects to receive approximately $2 million in non-dilutive R&D tax credits repayable to the company in cash from its U.K. subsidiary in 2H-26Offering net proceeds, together with funds expected to be received via U.K. subsidiary, expected to provide cash runway into 2027Company expects to receive approvals in the U.S., U.K. and Europe for OST-HER2 in the prevention of delay of recurrent, fully resected, pulmonary metastatic osteosarcoma in the second half of 2026 New York, New York--(Newsfile Corp. - April 2, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Co

    4/2/26 5:15:00 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update

    December 2025 Type C Meeting confirmed immune biomarkers suitability to establish surrogate clinical efficacy that could support BLA under Accelerated Approval PathwayPre-specified clinical outcomes data correlates with Immune biomarker signatureCompany positioned to review completed Phase 2b clinical & biomarker data and confirmatory Phase 3 trial protocol with U.S. FDA, EMA and U.K. MHRA in 2Q/26Company expects to initiate confirmatory Phase 3 trial in Australia in 3Q/26Company anticipates receiving a BLA under Accelerated Approval Program in the U.S. and Conditional Marketing Authorizations in Europe and in the U.K. in 2H/26New York, New York--(Newsfile Corp. - March 31, 2026) - OS Therap

    3/31/26 7:40:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mckean-Dieser Avril Suzette

    4 - OS Therapies Inc (0001795091) (Issuer)

    2/13/26 4:43:41 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Search Theodore F.

    4 - OS Therapies Inc (0001795091) (Issuer)

    2/13/26 4:43:05 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ciccio John

    4 - OS Therapies Inc (0001795091) (Issuer)

    2/13/26 4:42:41 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on OS Therapies with a new price target

    Lake Street initiated coverage of OS Therapies with a rating of Buy and set a new price target of $19.00

    4/2/25 8:01:55 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    SEC Filings

    View All

    OS Therapies Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - OS Therapies Inc (0001795091) (Filer)

    4/2/26 5:25:09 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by OS Therapies Incorporated

    424B5 - OS Therapies Inc (0001795091) (Filer)

    4/2/26 5:00:33 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Incorporated filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - OS Therapies Inc (0001795091) (Filer)

    3/31/26 4:20:28 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Financials

    Live finance-specific insights

    View All

    OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update

    December 2025 Type C Meeting confirmed immune biomarkers suitability to establish surrogate clinical efficacy that could support BLA under Accelerated Approval PathwayPre-specified clinical outcomes data correlates with Immune biomarker signatureCompany positioned to review completed Phase 2b clinical & biomarker data and confirmatory Phase 3 trial protocol with U.S. FDA, EMA and U.K. MHRA in 2Q/26Company expects to initiate confirmatory Phase 3 trial in Australia in 3Q/26Company anticipates receiving a BLA under Accelerated Approval Program in the U.S. and Conditional Marketing Authorizations in Europe and in the U.K. in 2H/26New York, New York--(Newsfile Corp. - March 31, 2026) - OS Therap

    3/31/26 7:40:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

    75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)100% of patients who achieved 12 month event free survival achieved 2 year overall survivalNew York, New York--(Newsfile Corp. - October 10, 2025) - OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced statistically significant positive final 2-year overall survival data from the Company's Phase 2b trial of off-the-shelf immunotherapy candidate OST-HER2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma (the "Fu

    10/10/25 6:00:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

    New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will report second quarter 2025 financial results ended June 30, 2025 and provide a business update on the morning of Tuesday, August 19, 2025.About OS TherapiesOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initia

    8/14/25 5:44:00 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Leadership Updates

    Live Leadership Updates

    View All

    OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

    Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma regulatory advice and oncology pipeline prioritizationNew York, New York--(Newsfile Corp. - April 8, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced that Craig Eagle, MD, was appointed to the Company's newly-formed strategic advisory board. The Company's strategic advisory board is being formed to assist the Company in fine-tuning its osteosarcoma regulatory execution plan and to help develop a detailed pipeline

    4/8/26 11:38:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

    Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

    1/29/25 9:22:00 AM ET
    $ADXS
    $OSTX
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $OSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OS Therapies Incorporated

    SC 13G - OS Therapies Inc (0001795091) (Subject)

    8/28/24 4:30:09 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care